Literature DB >> 17906194

Tumor mRNA expression profiles predict responses to chemotherapy.

John D Minna, Luc Girard, Yang Xie.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17906194     DOI： 10.1200/JCO.2007.12.3968

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  A lung cancer molecular prognostic test ready for prime time.

Authors:  Yang Xie; John D Minna
Journal:  Lancet       Date:  2012-03-03       Impact factor: 79.321

2.  Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.

Authors:  Paul D Williams; Charles R Owens; Jaroslaw Dziegielewski; Christopher A Moskaluk; Paul W Read; James M Larner; Michael D Story; William A Brock; Sally A Amundson; Jae K Lee; Dan Theodorescu
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 3.  Radiogenomics predicting tumor responses to radiotherapy in lung cancer.

Authors:  Amit K Das; Marcus H Bell; Chaitanya S Nirodi; Michael D Story; John D Minna
Journal:  Semin Radiat Oncol       Date:  2010-07       Impact factor: 5.934

4.  Adaptive prediction model in prospective molecular signature-based clinical studies.

Authors:  Guanghua Xiao; Shuangge Ma; John Minna; Yang Xie
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

Review 5.  Data-driven methods to discover molecular determinants of serious adverse drug events.

Authors:  A P Chiang; A J Butte
Journal:  Clin Pharmacol Ther       Date:  2009-01-28       Impact factor: 6.875

6.  Predicting the future for people with lung cancer.

Authors:  Yang Xie; John D Minna
Journal:  Nat Med       Date:  2008-08       Impact factor: 53.440

Review 7.  Utilizing the molecular gateway: the path to personalized cancer management.

Authors:  Jonathan B Overdevest; Dan Theodorescu; Jae K Lee
Journal:  Clin Chem       Date:  2009-02-26       Impact factor: 8.327

8.  Molecular profiling for personalized cancer care.

Authors:  Raheela Ashfaq
Journal:  Clin Exp Metastasis       Date:  2012-06-08       Impact factor: 5.150

Review 9.  Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Authors:  Natasa Snoj; Philippe L Bedard; Evandro de Azambuja; Fatima Cardoso; Martine Piccart
Journal:  Breast Cancer Res       Date:  2009-01-16       Impact factor: 6.466

10.  APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.

Authors:  Russell D Petty; Leslie M Samuel; Graeme I Murray; Graham MacDonald; Terrence O'Kelly; Malcolm Loudon; Norman Binnie; Emad Aly; Aileen McKinlay; Weiguang Wang; Fiona Gilbert; Scot Semple; Elaina S R Collie-Duguid
Journal:  BMC Cancer       Date:  2009-12-11       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.